Kyverna Deprioritizes Rapid Manufactured KYV-102

In the same November 12 disclosure, Kyverna said it elected to deprioritize KYV-102, its rapid whole-blood manufacturing follow-on CAR-T program. The company will focus on late-stage miv-cel neurologic indications and lifecycle measures to improve…






